Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-CD19 Antibody
Copy Product Info
🥰Excellent
Catalog No. T9901A-1348
Anti-CD19 Antibody (Tafasitamab) is an Fc-engineered humanized monoclonal antibody that specifically targets the CD19 antigen on B lymphocytes. The compound mediates potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) by enhanced binding to Fcgamma receptors on effector cells, thereby directly inducing cell death and depleting malignant B cells. It serves as a pharmacological tool for investigating diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies.
Anti-CD19 Antibody
Anti-CD19 Antibody
Copy Product Info🥰Excellent
Catalog No. T9901A-1348
Anti-CD19 Antibody (Tafasitamab) is an Fc-engineered humanized monoclonal antibody that specifically targets the CD19 antigen on B lymphocytes. The compound mediates potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) by enhanced binding to Fcgamma receptors on effector cells, thereby directly inducing cell death and depleting malignant B cells. It serves as a pharmacological tool for investigating diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies.
Product information is being updated, if you want to purchase, please click the bulk custom button.
Add to Quotation
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Anti-CD19 Antibody (Tafasitamab) is an Fc-engineered humanized monoclonal antibody that specifically targets the CD19 antigen on B lymphocytes. The compound mediates potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) by enhanced binding to Fcgamma receptors on effector cells, thereby directly inducing cell death and depleting malignant B cells. It serves as a pharmacological tool for investigating diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. |
| In vitro | In cytotoxicity assays using lymphoma cell lines (Raji, Ramos), Anti-CD19 Antibody demonstrated superior potency compared to non-engineered antibodies, mediating robust ADCC (EC50: 0.9-4.3 pM) and ADCP [1]. |
| In vivo | In Raji lymphoma xenograft models, systemic administration of Anti-CD19 Antibody caused dose-dependent tumor regression and significantly prolonged survival compared to control antibodies [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CD19 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Anti-CD19 Antibody | purchase Anti-CD19 Antibody | Anti-CD19 Antibody cost | order Anti-CD19 Antibody | Anti-CD19 Antibody in vivo | Anti-CD19 Antibody in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.